Bora Pharmaceuticals to buy GSK's Mississauga-based manufacturing facility
![](/46/pdcnewsitem/08/25/13/GSKBUILDINGARIELMATSTER%20(1).jpg)
CDMO Bora Pharmaceuticals said Monday it has agreed to acquire GlaxoSmithKline's Mississauga, Ontario (Canada) facility, which produces approximately 50 different products for more than 100 markets worldwide.
Bora -- which specializes in complex modified release manufacturing and solvent processing for non-sterile oral solid dosage forms -- said the agreement marks its latest phase of expansion as the site becomes its flagship North American facility.
It said the acquisition broadens its range of dosage forms, technical capabilities, and geographical locations, as well as enabling the multinational contract service provider to locally support its core markets of North America and Asia.
As part of the transaction, the facility's 400 manufacturing staff will be invited to join Bora Pharmaceuticals, which will continue to manufacture, under contract, the existing GSK product line for at least 5 years. GSK Pharmaceuticals and Consumer Healthcare employees, who currently work in office space at Mississauga will move to new locations within an agreed timeframe following the close of the transaction.
"We are excited to announce today the next phase of our expansion into North America with the acquisition of this world-class facility," said Bobby Sheng, CEO of Bora Pharmaceuticals. "The Mississauga-based facility is ideally suited with our intention to grow our technical capabilities and scale in the global CDMO marketplace."
According to Andrew Ehrat, Mississauga Site Director for GSK in Canada, the companies expect to complete the transaction by the end of 2020.
![Bora Pharmaceuticals Laboratories Inc.](https://www.cphi-online.com/c280920th_S-comp280920.jpg)
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance